FromAstraZeneca ([email protected])
Subject (90)Tagrisso plus savolitinib demonstrated 49% objective response rate in lung cancer patients
Preheader (150)Tagrisso plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification
Arial
Text Analysis
Body Words249
Subject Words12
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px832 px
X-Spam Score0.4
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeOvernight
